CClinicalTrials.gg
TerminatedNCT04461210Updated Jul 8, 2025Results posted

Vulvodynia Pain Thresholds

An observational study in Vulvodynia, sponsored by State University of New York at Buffalo. Terminated at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by State University of New York at Buffalo · Observational

Why this study was terminated
Investigator retired and no other investigator was able to resume the study.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
18
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Annotated pain maps will be created showing region and size of areas sensitive to mechanical stimulus in both women affected by vulvar pain and unaffected control patients.

Read the detailed description

The investigators will develop annotated pain maps showing region and size of areas sensitive to mechanical stimulus. The pain maps will be created by combining IR images, photographs, and clinical input, and will be correlated with patient co-morbidities. The IR images will assess for areas of inflammation and increased skin temperature. Pain maps will be created with patient response to mechanical stimulation with a cotton swab and will be overlaid on the thermographic images. Through this combination of measurements, the investigators plan to expand the diagnostic tools used in patient care as well as on the classification of this heterogeneous disorder.

02

Conditions studied

  • Vulvodynia

Browse trials for

03

In context

Vulvodynia

106 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.

This study's enrollment of 18 is below the median of 167 across 24 observational studies indexed under Vulvodynia.

Browse Vulvodynia studies →

Lead sponsor

State University of New York at Buffalo is the lead sponsor of 287 studies on the registry; 65 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Women with localized, provoked vulvodynia and healthy controls without vulvar pain or other vulvar disorders.

Inclusion criteria

  • women meeting criteria for vulvodynia women seeking care for routine gynecologic exam

Exclusion criteria

Exclusion Criteria:

  • women less than 18 years of age current pregnancy women with vulvar or vaginal disorder other than pain
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
18 participants (actual)
Patient registry
No

Groups and cohorts

  • Vulvodynia

    Women with localized, provoked vulvodynia

    Diagnostic Test: Thermographic Imaging and Mechanical Pain Assessment

  • Health Controls

    Women without vulvar pain or other vulvar disorders.

    Diagnostic Test: Thermographic Imaging and Mechanical Pain Assessment

Interventions

  • Diagnostic testThermographic Imaging and Mechanical Pain Assessment

    Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera

06

What researchers measure

Primary outcomes

  1. Annotated Pain Mapping

    Develop annotated pain maps showing region and size of area sensitive to mechanical stimulus. A cotton swab is used to lightly touch the vulva in 18 different locations and participant's assessment of pain on a scale of 0-10 is recorded.

    Time frame: Duration of study visit, approximately 1 hour

  2. Quantitative Pain Description of the Vulva With Touch.

    The vulva is lightly touched with a cotton swab at 18 locations of the vulva. Participants rate pain at each location on a scale of 0-10, with 0 being no pain and 10 being worst. Only the pain scores from the 7 points of the inner vulva are presented here, since that is the primary site of pain in women with provoked vulvodynia.

    Time frame: Immediate

Secondary outcomes

  1. Thermographic Imaging of the Vulva.

    Images of the vulva taken (prior to any provocation) with specialized temperature-sensitive camera. These images will then be overlaid on the annotated pain map.

    Time frame: Duration of study visit, approximately 1 hour

  2. Thermographic Imaging of the Vulva

    Images of the vulva taken with specialized heat-sensitive camera.

    Time frame: Duration of study visit, about 1 hour

07

Results

Posted Jul 8, 2025

Participant flow

Participant flow — Overall Study
MilestoneVulvodyniaHealthy Controls
Started414
Completed414
Not completed00

Outcome measures

PrimaryAnnotated Pain Mapping

Develop annotated pain maps showing region and size of area sensitive to mechanical stimulus. A cotton swab is used to lightly touch the vulva in 18 different locations and participant's assessment of pain on a scale of 0-10 is recorded.

Time frame:
Duration of study visit, approximately 1 hour
Reported as:
Mean · score on a scale
Annotated Pain Mapping
score on a scaleVulvodyniaHealthy Controls
Annotated Pain Mapping4.7 (0 to 10)1.9 (0 to 10)
PrimaryQuantitative Pain Description of the Vulva With Touch.

The vulva is lightly touched with a cotton swab at 18 locations of the vulva. Participants rate pain at each location on a scale of 0-10, with 0 being no pain and 10 being worst. Only the pain scores from the 7 points of the inner vulva are presented here, since that is the primary site of pain in women with provoked vulvodynia.

Time frame:
Immediate
Reported as:
Mean · score on a scale
Quantitative Pain Description of the Vulva With Touch.
score on a scaleVulvodyniaHealth Controls
Quantitative Pain Description of the Vulva With Touch.3.5 ± 4.71.1 ± 1.9
SecondaryThermographic Imaging of the Vulva.

Images of the vulva taken (prior to any provocation) with specialized temperature-sensitive camera. These images will then be overlaid on the annotated pain map.

Time frame:
Duration of study visit, approximately 1 hour
Reported as:
Mean · temperature in Fahrenheit
Thermographic Imaging of the Vulva.
temperature in FahrenheitVulvodyniaHealth Controls
maximum temperature36.4 ± 0.2136.8 ± 0.58
minimum temperature32.2 ± 1.831.9 ± 1.65
SecondaryThermographic Imaging of the Vulva

Images of the vulva taken with specialized heat-sensitive camera.

Time frame:
Duration of study visit, about 1 hour
Reported as:
Mean · temperature in Fahrenheit
Thermographic Imaging of the Vulva
temperature in FahrenheitVulvodyniaHealth Controls
maximum temperature36.9 ± 0.4737.4 ± 0.47
minimum temperature33.2 ± 1.834.3 ± 2.1

Adverse events

Collected over Event reporting occurred for the duration of the participant's time in the study, generally about 1 hour.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vulvodynia0/4 (0%)0/4 (0%)0/4 (0%)
Healthy Controls0/14 (0%)0/14 (0%)0/14 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)VulvodyniaHealthy ControlsTotal
Mean32 ± 1030 ± 9.330.6 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)VulvodyniaHealthy ControlsTotal
Female41418
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VulvodyniaHealthy ControlsTotal
Hispanic or Latino000
Not Hispanic or Latino41418
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VulvodyniaHealthy ControlsTotal
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American011
White41115
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)VulvodyniaHealthy ControlsTotal
United States41418
08

Study locations

1 site
  • UBMD Obstetrics and Gynecology
    Buffalo, New York 14203, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 29, 2024
  • Informed consent form · Feb 28, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04461210
Lead sponsor
State University of New York at Buffalo
Collaborators
National Center for Advancing Translational Sciences (NCATS)
Responsible party
Vanessa Barnabei (Professor, State University of New York at Buffalo) — Principal investigator
First posted
Jul 8, 2020
Start date
Feb 28, 2022
Primary completion
Jan 6, 2024
Completion
Jan 6, 2024
Results posted
Jul 8, 2025
Last update
Jul 8, 2025

Study contacts

Vanessa M Barnabei, MD, PhD
principal investigator · University at Buffalo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion